• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Symptomatic hyperbilirubinemia secondary to dapsone-induced hemolysis and atazanavir therapy.由于使用了达普司酮导致的溶血和阿扎那韦治疗引起的症状性高胆红素血症。
Antimicrob Agents Chemother. 2012 Feb;56(2):1081-3. doi: 10.1128/AAC.05806-11. Epub 2011 Nov 28.
2
[Safety of atazanavir in patients with HIV and hepatitis B and/or C virus coinfection].[阿扎那韦在合并感染人类免疫缺陷病毒与乙型和/或丙型肝炎病毒患者中的安全性]
Enferm Infecc Microbiol Clin. 2008 Dec;26 Suppl 17:45-8. doi: 10.1016/S0213-005X(08)76620-5.
3
Dapsone safety in hematology patients: Pathways to optimizing Pneumocystis jirovecii pneumonia prophylaxis in hematology malignancy and transplant recipients.氨苯砜在血液病患者中的安全性：优化血液系统恶性肿瘤和移植受者预防耶氏肺孢子菌肺炎的途径。
Transpl Infect Dis. 2018 Dec;20(6):e12968. doi: 10.1111/tid.12968. Epub 2018 Aug 4.
4
[Adverse effects of atazanavir].[阿扎那韦的不良反应]
Enferm Infecc Microbiol Clin. 2008 Dec;26 Suppl 17:41-4. doi: 10.1016/S0213-005X(08)76619-9.
5
Maternal atazanavir usage in HIV-infected pregnant women and the risk of maternal and neonatal hyperbilirubinemia.感染艾滋病毒的孕妇使用阿扎那韦与母婴高胆红素血症风险
J Acquir Immune Defic Syndr. 2013 Aug 15;63(5):e158-9. doi: 10.1097/QAI.0b013e31829baf03.
6
Acute generalised exanthematous pustulosis induced by Pneumocystis jirovecii pneumonia prophylaxis with dapsone.由氨苯砜预防耶氏肺孢子菌肺炎引发的急性泛发性脓疱性皮病。
Int J STD AIDS. 2013 Sep;24(9):745-7. doi: 10.1177/0956462413482813. Epub 2013 Aug 28.
7
Adverse reactions associated with dapsone therapy in HIV-positive patients: a case presentation and review.HIV 阳性患者中与氨苯砜治疗相关的不良反应：病例报告及文献复习
AIDS Read. 2006 Jan;16(1):47-8, 53-5; discussion 54-5.
8
Pharmacogenetic testing can identify patients taking atazanavir at risk for hyperbilirubinemia.药物遗传学检测可识别服用阿扎那韦有发生高胆红素血症风险的患者。
J Acquir Immune Defic Syndr. 2015 May 1;69(1):e36-7. doi: 10.1097/QAI.0000000000000540.
9
Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors.与包括HIV-1蛋白酶抑制剂在内的抗逆转录病毒疗法相关的药物性肝损伤。
Clin Infect Dis. 2004 Mar 1;38 Suppl 2:S90-7. doi: 10.1086/381444.
10
Effect of the UGT1A1*28 allele on unconjugated hyperbilirubinemia in HIV-positive patients receiving Atazanavir: a systematic review.UGT1A1*28 等位基因对接受阿扎那韦的 HIV 阳性患者未结合高胆红素血症的影响：系统评价。
Ann Pharmacother. 2013 Apr;47(4):561-72. doi: 10.1345/aph.1R550. Epub 2013 Apr 2.

引用本文的文献

1
Heme-Induced Macrophage Phenotype Switching and Impaired Endogenous Opioid Homeostasis Correlate with Chronic Widespread Pain in HIV.血红素诱导的巨噬细胞表型转换和内源性阿片肽稳态失调与 HIV 相关的慢性广泛性疼痛相关。
Cells. 2023 Jun 6;12(12):1565. doi: 10.3390/cells12121565.
2
Precision medicine: retrospective chart review and data analysis of 200 patients on dapsone combination therapy for chronic Lyme disease/post-treatment Lyme disease syndrome: part 1.精准医学：对200例接受氨苯砜联合疗法治疗慢性莱姆病/莱姆病治疗后综合征患者的病历回顾与数据分析：第1部分
Int J Gen Med. 2019 Feb 18;12:101-119. doi: 10.2147/IJGM.S193608. eCollection 2019.

本文引用的文献

1
Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study.替拉那韦/利托那韦每日 1 次与洛匹那韦/利托那韦每日 2 次，分别联合替诺福韦和恩曲他滨，用于治疗初治 HIV-1 感染患者的疗效和安全性：CASTLE 研究 96 周结果。
J Acquir Immune Defic Syndr. 2010 Mar;53(3):323-32. doi: 10.1097/QAI.0b013e3181c990bf.
2
Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia.影响阿扎那韦血药浓度及严重高胆红素血症风险的遗传因素。
AIDS. 2007 Jan 2;21(1):41-6. doi: 10.1097/QAD.0b013e328011d7c1.
3
Atazanavir plasma concentrations vary significantly between patients and correlate with increased serum bilirubin concentrations.阿扎那韦的血浆浓度在患者之间差异显著，且与血清胆红素浓度升高相关。
HIV Clin Trials. 2006 Jan-Feb;7(1):34-8. doi: 10.1310/0KX0-H9VH-99EE-5D0L.
4
Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-->T polymorphism at the multidrug resistance gene 1.多药耐药基因1的3435C→T多态性可预测阿扎那韦的血浆水平及高胆红素血症风险。
Clin Infect Dis. 2006 Jan 15;42(2):291-5. doi: 10.1086/499056. Epub 2005 Dec 8.
5
In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation.阿扎那韦及其他HIV蛋白酶抑制剂对尿苷二磷酸葡萄糖醛酸基转移酶的体外抑制作用及其该特性与体内胆红素葡萄糖醛酸化的关系。
Drug Metab Dispos. 2005 Nov;33(11):1729-39. doi: 10.1124/dmd.105.005447. Epub 2005 Aug 23.
6
DAPSONE-INDUCED HAEMOLYSIS.氨苯砜所致溶血
Br Med J. 1963 Sep 14;2(5358):662-4. doi: 10.1136/bmj.2.5358.662.
7
Atazanavir.阿扎那韦
Drugs. 2003;63(16):1679-93; discussion 1694-5. doi: 10.2165/00003495-200363160-00003.
8
Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects.48周2期临床试验（AI424 - 007）结果：一项在初治抗逆转录病毒治疗受试者中进行的阿扎那韦三种剂量与去羟肌苷和司他夫定联合用药的剂量范围、安全性和疗效对比试验。
J Acquir Immune Defic Syndr. 2003 Jan 1;32(1):18-29. doi: 10.1097/00126334-200301010-00004.
9
Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Group.对于不能耐受甲氧苄啶、磺胺类药物或两者的HIV感染患者，用阿托伐醌与氨苯砜预防卡氏肺孢子虫肺炎的比较。艾滋病临床研究社区项目和艾滋病临床试验组。
N Engl J Med. 1998 Dec 24;339(26):1889-95. doi: 10.1056/NEJM199812243392604.
10
The predictive value of serum haptoglobin in hemolytic disease.血清触珠蛋白在溶血性疾病中的预测价值。
JAMA. 1980 May 16;243(19):1909-11.

由于使用了达普司酮导致的溶血和阿扎那韦治疗引起的症状性高胆红素血症。

Symptomatic hyperbilirubinemia secondary to dapsone-induced hemolysis and atazanavir therapy.

机构信息

The University of Texas Medical Branch, Department of Internal Medicine—Division of Infectious Diseases, Galveston, Texas, USA.

出版信息

Antimicrob Agents Chemother. 2012 Feb;56(2):1081-3. doi: 10.1128/AAC.05806-11. Epub 2011 Nov 28.

DOI:10.1128/AAC.05806-11
PMID:22123706
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3264226/
Abstract

The antiretroviral agent atazanavir is associated with mild asymptomatic hyperbilirubinemia. We report two cases of symptomatic hyperbilirubinemia attributed to atazanavir in conjunction with the Pneumocystis jirovecii pneumonia prophylaxis agent dapsone. Symptoms and laboratory evidence of hemolysis resolved upon discontinuation of dapsone, enabling successful antiretroviral therapy. Symptomatic hyperbilirubinemia due to hemolytic anemia is a potential adverse event when using the combination of atazanavir and dapsone in the treatment of patients with the human immunodeficiency virus.

摘要

抗逆转录病毒药物阿扎那韦可引起轻度无症状性高胆红素血症。我们报告了两例与预防卡氏肺孢子虫肺炎的药物氨苯砜合用引起的有症状性高胆红素血症的病例。停用氨苯砜后，症状和溶血性贫血的实验室证据得到缓解，从而成功地进行了抗逆转录病毒治疗。在治疗人类免疫缺陷病毒感染者时，阿扎那韦和氨苯砜联合使用时，由于溶血性贫血引起的症状性高胆红素血症是一种潜在的不良事件。